

Applicants: Paul Simmons et al.
Serial No.: 10/813,747
Filed : March 29, 2004
Page 2

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-78. (Cancelled)

79. (Currently Amended) A method of generating a tissue in a subject comprising administering to the subject a population of cells enriched for STRO-1^{bright} cells, or culture expanded colony-forming-unit-fibroblasts (CFU-F) derived therefrom, wherein such STRO-1^{bright} cells are mesenchymal precursor cells which comprise mesenchymal precursor cells capable of giving rise to ~~colony-forming unit-fibroblasts~~ (CFU-F) so as to generate the tissue in the subject.

80. (Cancelled).

81. (Currently Amended) The method of claim 80, wherein the mesenchymal tissue is smooth muscle, cardiac muscle, or endothelial, adipose, areolar, bone, cartilaginous, elastic, fibrous connective tissue or blood vessels tissue.

82. (Cancelled).

83. (Cancelled).

84. (Previously Presented) The method of claim 79, wherein the mesenchymal precursor cells carry at least one additional marker selected from the group of surface markers consisting of THY-1, VCAM-1, STRO-2, and CD146.

Applicants: Paul Simmons et al.
Serial No.: 10/813,747
Filed : March 29, 2004
Page 3

85. (Previously Presented) The method of claim 84, wherein the mesenchymal precursor cells carry the markers STRO-1 and VCAM-1.
86. (Withdrawn) The method of claim 79, wherein said STRO-1^{bright} cells in the enriched population comprise an exogenous nucleic acid that expresses a therapeutic agent.
87. (Withdrawn) The method of claim 79, wherein the tissue is bone marrow.
88. (Withdrawn) The method of claim 87, wherein the population of cells is preadsorbed onto a ceramic vehicle that is precoated with fibronectin and is implanted to augment bone marrow transplantation.
89. (Withdrawn) The method of claim 88, which further comprises administering haemopoietic cells to the subject.
90. (Previously Presented) The method of claim 79, wherein the STRO-1^{bright} cells are negative for at least one marker selected from the group consisting of CBFA-1, collagen type II, PPAR γ 2, and glycophorin A.